About 50% of all patients with cancer eventually develop anorexia/cachexia syndrome, which represents a complex clinical syndrome occurring in several illnesses, including cancer. The syndrome is characterized by systemic inflammation and primarily loss of body fat and body mass. In this review we shortly summarize the pathomechanism of anorexia/cachexia syndrome and list the current pharmacological approaches.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Treatment of choice for malignant gastric outlet obstruction: More than clearing the road.
World J Gastrointest Endosc
November 2024
Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province, China.
In this editorial, we comment on the in-press article in the concerning the treatment of malignant gastric outlet obstruction (mGOO). The original theory of treatment involves bypassing the obstruction or reenabling the patency of the passage. Conventional surgical gastroenterostomy provides long-term relief of symptoms in selected patients, with substantial morbidity and a considerable rate of delayed gastric emptying.
View Article and Find Full Text PDFGDF15 research from bench to bedside.
Cancer Cell
November 2024
St Vincent's Centre for Applied Medical Research, St Vincent's Hospital, Sydney, NSW 2010, Australia; The University of New South Wales, Sydney, NSW 2052, Australia. Electronic address:
Pre-clinical data suggest that increased circulating growth differentiation factor 15 (GDF15) is a cause of both anorexia/cachexia syndromes and hyperemesis gravidarum in pregnancy, serious conditions with no highly effective treatment. A phase 2 study of a therapeutic GDF15 monoclonal antibody in the New England Journal of Medicine suggests that effective treatment of anorexia/cachexia in cancer may be approaching.
View Article and Find Full Text PDFThe LEAP2 Response to Cancer-Related Anorexia-Cachexia Syndrome in Male Mice and Patients.
Endocrinology
September 2024
Center for Hypothalamic Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Article Synopsis
- The hormone ghrelin plays a protective role in cancer-related anorexia-cachexia syndrome (CACS), with its levels rising to help combat weight loss and anorexia in cancer patients.
- A study found that deleting ghrelin worsened body weight and fat loss in mice with cancer, while deleting LEAP2, a ghrelin antagonist, seemed to lessen the severity of CACS.
- In human patients with CACS, a lower ratio of plasma LEAP2 to total ghrelin was associated with better weight stability, indicating a possible protective mechanism against worsening CACS.
Family Members' Explanatory Models of Cancer Anorexia-Cachexia.
Healthcare (Basel)
August 2024
Rady Faculty of Health Sciences, College of Nursing, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
The experience of bearing witness to the lack of appetite and involuntary weight loss that characterizes cancer anorexia-cachexia syndrome (CACS) is reported to be stressful for family members. Research identifies that family members engage in a wide range of behaviors in response to a relative who shows minimal interest in eating and is literally 'wasting away' before their eyes. Some families, though concerned about the symptoms of CACS, do not dwell excessively on the patient's nutritional intake while others continually harass the patient to eat and petition health care providers for aggressive nutritional interventions to eat in an attempt to stave off further physical deterioration.
View Article and Find Full Text PDFDose-dependent effect of megestrol acetate supplementation in cancer patients with anorexia-cachexia syndrome: A meta-analysis.
J Cachexia Sarcopenia Muscle
August 2024
Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran.
There is inconsistent evidence relating to the effects of megestrol acetate (MA) supplementation on cancer patients suffering from anorexia-cachexia syndrome. This review aimed to examine the dose-response effect of MA supplementation in patients with cancer-associated anorexia/cachexia. Relevant keywords were searched in PubMed, Scopus and ISI Web of Science from inception to June 2023 for randomized controlled trials (RCTs) examining the effect of MA on pathologies in patients with cancer-associated cachexia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!